The importance of pathways to facilitate early diagnosis and treatment of patients with cardiac amyloidosis

Kwok, Chun Shing; Moody, William E.

Abstract

Cardiac amyloidosis (CA) is a condition caused by extracellular deposition of amyloid fibrils in the heart. It is an underdiagnosed disease entity which can present with a variety of cardiac and non-cardiac manifestations. Diagnosis usually follows an initial suspicion based on clinical evaluation or imaging findings before confirmation with subsequent imaging (echocardiography, cardiac magnetic resonance imaging, 3,3-diphosphono-1,2-propanodicarboxylic acid scintigraphy) in combination with biochemical screening for monoclonal dyscrasia (serum free light chains and serum and urine electrophoresis) and/or histology (bone marrow trephine, fat or endomyocardial biopsy). More than 95% of CA can be classified as either amyloid light-chain (AL) CA or amyloid transthyretin (ATTR) CA; these two conditions have very different management strategies. AL-CA, which may be associated with multiple myeloma, can be managed with chemotherapy agents, autologous stem cell transplantation, cardiac transplant and supportive therapies. For ATTR-CA, there is increasing importance in making an early diagnosis because of novel treatments in development, which have transformed this once incurable disease to a potentially treatable disease. Timely diagnosis is crucial as there may only be a small window of opportunity where patients can benefit from treatment beyond which therapies may be less effective. Reviewing the existing patient pathway provides a basis to better understand the complexities of real-world activities which may be important to help reduce missed opportunities related to diagnosis and treatment for patients with CA. With healthcare provider interest in improving the care of patients with CA, the development of an optimal care pathway for the condition may help reduce delays in diagnosis and treatment and thus enhance patient outcomes.

Citation

Kwok, C. S., & Moody, W. E. (in press). The importance of pathways to facilitate early diagnosis and treatment of patients with cardiac amyloidosis. Therapeutic Advances in Cardiovascular Disease, 17, 17539447231216318. https://doi.org/10.1177/17539447231216318

• Journal Article Type: Article
• Acceptance Date: Nov 7, 2023
• Online Publication Date: Dec 15, 2023
• Deposit Date: Jan 5, 2024
• Publicly Available Date: Jan 5, 2024
• Journal: Therapeutic Advances in Cardiovascular Disease
• Print ISSN: 1753-9447
• Publisher: SAGE Publications
• Peer Reviewed: Peer Reviewed
• Volume: 17
• Pages: 17539447231216318
• DOI: https://doi.org/10.1177/17539447231216318
• Keywords: management, treatment, pathways, cardiac amyloidosis